Listen to this Post
The legal storm surrounding Apple’s health technology intensifies as the U.S. International Trade Commission (ITC) launches a fresh investigation into the Apple Watch’s redesigned blood oxygen monitoring feature. The probe threatens to disrupt Apple Watch sales during the critical holiday season, highlighting the high stakes of intellectual property disputes in the booming wearable tech market. Months after Apple reintroduced the contested feature, questions remain about whether the tech giant has successfully navigated patent infringement claims or merely sidestepped them.
ITC Investigation Targets Apple’s Workaround
The ITC investigation, scheduled to conclude by April 2026, centers on Apple’s August redesign, which processes blood oxygen data on paired iPhones instead of directly on the watch. The key question: does this workaround respect Masimo’s pulse oximetry patents, or does it continue to infringe them? Should the commission find that Apple’s method still violates patent protections, U.S. imports of Apple Watch Series 9, Series 10, and Ultra 2 could face another ban, potentially hitting sales during the holiday season—a vital period for consumer electronics revenue.
Rising Stakes in a Multi-Year Patent Battle
This case is the latest chapter in a drawn-out legal conflict that has already cost Apple hundreds of millions. A federal jury recently ordered Apple to pay Masimo $634 million for infringing patents related to 43 million Apple Watches sold between 2020 and 2022. Previously, the ITC blocked certain Apple Watch imports in 2023, forcing Apple to disable blood oxygen monitoring for more than a year in the U.S. market. These repeated interruptions underscore the high cost of patent disputes for major tech companies.
Apple’s Technical Workaround
Apple’s solution shifts all blood oxygen calculations from the watch hardware to the iPhone’s Health app. Users can initiate measurements on their wrist but must view results on their phone. While U.S. Customs approved this redesign in August, Masimo contends that Apple bypassed proper notification procedures, leaving the company’s legal exposure uncertain.
Implications for Apple’s Health Strategy
The ongoing investigation has broader implications for Apple’s health technology strategy, which promotes the Apple Watch as a holistic wellness device. Any ruling against Apple could undermine consumer confidence in the brand’s health monitoring capabilities and disrupt its position in the competitive wearable market. Apple, however, remains defiant, pledging to appeal unfavorable rulings and asserting that Masimo’s patents expired in 2022. Meanwhile, leadership changes at Masimo, including the recent departure of CEO Joe Kiani, add further unpredictability to potential settlements.
What Undercode Say:
Apple’s persistent legal challenges with Masimo highlight the delicate balance between innovation and intellectual property compliance in the tech sector. By moving blood oxygen calculations to the iPhone, Apple demonstrates a technical workaround designed to preserve functionality without directly violating patents—but the ITC’s scrutiny signals that legal nuance matters as much as engineering ingenuity.
This case also exposes the risks tech giants face when integrating medical-grade technologies. Unlike consumer features such as messaging or music, health monitoring devices operate in regulated domains, where patent protection intersects with consumer safety. A misstep can trigger not just financial penalties but regulatory action, import bans, and reputational damage.
Apple’s approach reflects a broader strategy in high-stakes patent disputes: innovate around the problem while appealing legal setbacks. However, relying on patent expiration as a defense may prove insufficient, especially when rival companies can argue procedural missteps in redesign notifications. The ITC’s review emphasizes that technical adjustments must align with both the letter and the spirit of patent law.
The financial stakes are enormous. Apple’s sales of Series 9, Series 10, and Ultra 2 models could be jeopardized during the holiday shopping season, potentially reducing revenue by hundreds of millions in a critical quarter. Masimo, meanwhile, strengthens its position as a patent holder asserting the value of medical technology innovations. The departure of its CEO introduces uncertainty, yet the company’s legal and intellectual property teams remain active, suggesting that the dispute is far from over.
Strategically, Apple may use this scenario to emphasize its commitment to consumer health while subtly pressuring patent holders to negotiate. The outcome could reshape the competitive landscape for wearable health technology, setting precedents for how much companies can redesign products to circumvent existing patents. Moreover, Apple’s repeated legal maneuvers illustrate the growing tension between rapid tech innovation and traditional patent law enforcement.
In the long term, the case underscores a vital lesson for tech companies: scaling medical features globally requires meticulous attention to patents, regulatory compliance, and procedural transparency. Apple’s experience may serve as a cautionary tale for emerging health tech firms seeking to integrate complex biomedical functions without infringing on intellectual property.
Fact Checker Results
✅ Apple’s ITC investigation into blood oxygen monitoring is confirmed.
✅ Federal jury awarded Masimo $634 million in patent infringement damages.
❌ Claims that Apple’s workaround completely avoids patent infringement remain unverified.
Prediction
📊 Apple will likely appeal any negative ITC rulings, potentially delaying import bans until 2026.
📊 Holiday season sales of Series 9, Series 10, and Ultra 2 models may experience temporary disruption.
📊 The dispute could encourage other tech companies to innovate around patent constraints while emphasizing procedural compliance.
🕵️📝✔️Let’s dive deep and fact‑check.
References:
Reported By: timesofindia.indiatimes.com
Extra Source Hub (Possible Sources for article):
https://www.reddit.com
Wikipedia
OpenAi & Undercode AI
Image Source:
Unsplash
Undercode AI DI v2
Bing
🔐JOIN OUR CYBER WORLD [ CVE News • HackMonitor • UndercodeNews ]
📢 Follow UndercodeNews & Stay Tuned:
𝕏 formerly Twitter 🐦 | @ Threads | 🔗 Linkedin | 🦋BlueSky | 🐘Mastodon
